Paul Keck
Psychiatry · Cincinnati, OHNPI 1710062872
Payments from drug & device makers
Across 676 payments — averaging $1092.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$187K
- AbbVie$181K
- Teva Pharmaceuticals USA, Inc.$114K
- Alkermes, Inc.$112K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$78K
- Otsuka America Pharmaceutical, Inc.$28K
- plus $39K from 6 others
What the payments were for
- Consulting fees$176,54924%
- Speaking & faculty fees$523,35071%
- Travel & lodging$27,2074%
- Food & beverage$11,2912%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 170 | $186,709 |
| AbbVie(2 entities) | 173 | $180,683 |
| Teva Pharmaceuticals USA, Inc. | 78 | $114,199 |
| Alkermes, Inc. | 114 | $112,330 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 72 | $77,707 |
| Otsuka America Pharmaceutical, Inc. | 32 | $27,945 |
| Eli Lilly | 5 | $11,585 |
| Merck | 11 | $10,783 |
| Vanda Pharmaceuticals Inc. | 14 | $8,569 |
| Sunovion Pharmaceuticals Inc. | 5 | $3,566 |
| Johnson & Johnson | 1 | $2,525 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,924 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$432,557
- Auvelity$183,946
- VRAYLAR$168,206
- CAPLYTA$76,398
- AUSTEDO$75,655
- Austedo XR$36,233
- ABILIFY MAINTENA$27,542
- Fanapt$8,197
- LATUDA$3,485
- ABILIFY ASIMTUFII$2,808
- SPRAVATO$2,525
How this compares
$738,524 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $21,499 |
| Aripiprazole | 16 | $2,955 |
| Quetiapine Fumarate | 14 | $704 |
| Mirtazapine | 18 | $676 |
| Bupropion Hcl SrBupropion Hcl | 24 | $510 |
| Gabapentin | 20 | $369 |
| Trazodone Hcl | 30 | $284 |
| Escitalopram Oxalate | 13 | $257 |
| Lamotrigine | 21 | $221 |
| Clonazepam | 18 | $192 |
| Fluoxetine Hcl | 13 | $165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $186,709 | $21,49915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Cincinnati
- Henry NasrallahCincinnati$3.8M
- Caleb AdlerCincinnati$2M
- Peter BoxerCincinnati$718K
- Tracey SkaleCincinnati$674K
- Lesley ArnoldCincinnati$620K
- Stephen PolandCincinnati$440K
- Fabiano NeryCincinnati$391K
- Jeffrey StrawnCincinnati$336K
- Helen FarrellCincinnati$277K
- Janell LundgrenCincinnati$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.